From stopping the immune attack to regrowing beta cells in the body, JDRF’s disease-modifying therapies portfolio is a key component of our efforts to finding cures for T1D.
T1D is a progression. There are people whose own immune system has begun attacking the insulin producing beta cells, but they are not symptomatic yet. There are also people who have had T1D for decades and have lost nearly all insulin production. Disease-modifying therapies are aimed at helping everyone with T1D—regardless of where they are on the disease continuum.
Learn more about this promising research, including one therapy under review at the FDA.